Chimeric Therapeutics Limited (ASX:CHM)
Australia flag Australia · Delayed Price · Currency is AUD
0.0020
0.00 (0.00%)
Mar 10, 2026, 4:10 PM AEST

Chimeric Therapeutics Ratios and Metrics

Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year
CurrentFY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020
Period Ending
Mar '26 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21 2020
Market Capitalization
9818193996
Upgrade
Market Cap Growth
-6.49%-53.99%-9.01%-50.79%-59.22%-
Upgrade
Enterprise Value
63141626101
Upgrade
Last Close Price
0.000.000.020.040.090.27
Upgrade
PS Ratio
0.910.642.354.2714.95-
Upgrade
PB Ratio
-2.924.087.093.401.523.82
Upgrade
P/TBV Ratio
----3.258.49
Upgrade
EV/Sales Ratio
0.650.241.883.479.82-
Upgrade
Net Debt / Equity Ratio
0.83-2.92-1.24-0.42-0.71-0.89
Upgrade
Net Debt / EBITDA Ratio
0.591.060.270.101.351.60
Upgrade
Net Debt / FCF Ratio
0.300.790.410.141.402.53
Upgrade
Asset Turnover
0.790.690.400.160.07-
Upgrade
Quick Ratio
0.680.710.310.612.333.05
Upgrade
Current Ratio
0.690.720.320.642.353.08
Upgrade
Return on Equity (ROE)
-1290.99%-469.35%-308.21%-165.25%-62.55%-120.59%
Upgrade
Return on Assets (ROA)
-26.96%-22.01%-40.86%-54.54%-25.52%-50.84%
Upgrade
Return on Capital Employed (ROCE)
365.20%-93.20%-237.70%-325.20%-56.40%-50.90%
Upgrade
Earnings Yield
-212.60%-129.40%-71.52%-134.60%-40.63%-15.75%
Upgrade
FCF Yield
--90.26%-43.02%-84.69%-33.65%-9.22%
Upgrade
Buyback Yield / Dilution
-168.67%-94.34%-60.57%-20.37%-97.88%-
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.